Latigo Biotherapeutics, Inc. — Form 8-K
Filed September 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Latigo Biotherapeutics (Nasdaq: LTGO), a clinical-stage biotech, completed an upsized IPO in August 2026 raising $397.4M gross proceeds (including full underwriter option exercise), with cash sufficient to fund operations into 2029. Lead candidate onzotrigine published positive Phase 2 results in NEJM for moderate-to-severe acute post-surgical pain, meeting primary endpoint with high statistical significance and opioid-sparing potential. Company appointed Naomi Lowy, M.D. (former FDA deputy director of pain division) as SVP regulatory affairs; Q2 2026 R&D expenses were $21.2M, G&A $4.6M, net loss $25.8M.
Why this rating
IPO capital infusion ($397.4M) is transformational for clinical-stage biotech; positive NEJM publication validates lead program. Material but pre-revenue; execution risk remains high on Phase 3 trials ahead.
Tradability signal
NO TRADE
No trade: positive news with only +0.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.34% over 4 hrs, n=27).
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $22.48 ▲ 0.00% | at our read · unknown $22.48 | +10 min · unknown $22.48 ▲ 0.00% | +30 min · unknown $22.48 ▲ 0.00% | +1 hr · unknown $22.48 ▲ 0.00% | +4 hrs pending |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.